Medical AI in China—and globally—has long been trapped in interlocking chicken-and-egg problems: you need clinical data to build good models, regulatory approval to deploy, and deployment evidence to earn approval. A Chinese domestic player, highlighted by QbitAI, is reported to have navigated this full end-to-end gauntlet. If validated, the breakthrough could offer a replicable commercial template for the broader medical AI sector in China.
This controversy stems from strict U.S. legal restrictions on aviation accident investigation data. Under federal law, the National Transportation Safety Board…
In the latest issue of Import AI 440, author Jack Clark delves into three key structural trends facing AI development today: the Red Queen Effect, the…